DK97890D0 - Fremgangsmaade til fremstilling af mevalolactonanaloge - Google Patents
Fremgangsmaade til fremstilling af mevalolactonanalogeInfo
- Publication number
- DK97890D0 DK97890D0 DK097890A DK97890A DK97890D0 DK 97890 D0 DK97890 D0 DK 97890D0 DK 097890 A DK097890 A DK 097890A DK 97890 A DK97890 A DK 97890A DK 97890 D0 DK97890 D0 DK 97890D0
- Authority
- DK
- Denmark
- Prior art keywords
- hydrogen
- benzyloxy
- phenoxy
- trifluoromethyl
- fluoro
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 239000001257 hydrogen Substances 0.000 abstract 12
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 6
- -1 t-butoxy Chemical group 0.000 abstract 6
- 125000001153 fluoro group Chemical group F* 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44366882A | 1982-11-22 | 1982-11-22 | |
US44366882 | 1982-11-22 | ||
US54885083A | 1983-11-04 | 1983-11-04 | |
US54885083 | 1983-11-04 | ||
EP8300308 | 1983-11-18 | ||
PCT/EP1983/000308 WO1984002131A1 (en) | 1982-11-22 | 1983-11-18 | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
Publications (4)
Publication Number | Publication Date |
---|---|
DK97890D0 true DK97890D0 (da) | 1990-04-19 |
DK97890A DK97890A (da) | 1990-04-19 |
DK165244B DK165244B (da) | 1992-10-26 |
DK165244C DK165244C (da) | 1993-03-22 |
Family
ID=27033614
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK359284A DK359284A (da) | 1982-11-22 | 1984-07-20 | Mevalolactonanaloge |
DK097890A DK165244C (da) | 1982-11-22 | 1990-04-19 | Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK359284A DK359284A (da) | 1982-11-22 | 1984-07-20 | Mevalolactonanaloge |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0114027B1 (da) |
JP (1) | JPH0347167A (da) |
AT (1) | ATE31718T1 (da) |
AU (1) | AU570021B2 (da) |
CA (1) | CA1210405A (da) |
CY (1) | CY1579A (da) |
DE (2) | DE3375137D1 (da) |
DK (2) | DK359284A (da) |
FI (1) | FI77228C (da) |
GR (1) | GR79042B (da) |
HK (1) | HK11191A (da) |
HU (1) | HU204253B (da) |
IE (1) | IE56262B1 (da) |
IL (1) | IL70286A (da) |
LU (1) | LU88670I2 (da) |
NL (1) | NL950022I2 (da) |
NZ (1) | NZ206338A (da) |
WO (1) | WO1984002131A1 (da) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4613610A (en) * | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
ATE60571T1 (de) * | 1984-12-04 | 1991-02-15 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
US5001255A (en) * | 1984-12-04 | 1991-03-19 | Sandoz Pharm. Corp. | Idene analogs of mevalonolactone and derivatives thereof |
US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
US4851427A (en) * | 1985-10-25 | 1989-07-25 | Sandoz Pharm. Corp. | Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use |
EP0221025A1 (en) * | 1985-10-25 | 1987-05-06 | Sandoz Ag | Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals |
IL83821A0 (en) * | 1986-09-10 | 1988-02-29 | Sandoz Ag | Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them |
US4751235A (en) * | 1986-12-23 | 1988-06-14 | Sandoz Pharm. Corp. | Anti-atherosclerotic indolizine derivatives |
US4735958A (en) * | 1986-12-22 | 1988-04-05 | Warner-Lambert Company | Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis |
US4898949A (en) * | 1987-02-25 | 1990-02-06 | Bristol-Myers Company | Intermediates for the preparation of antihypercholesterolemic tetrazole compounds |
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
US4894386A (en) * | 1987-04-15 | 1990-01-16 | Ici Americas Inc. | Aliphatic carboxamides |
US4904646A (en) * | 1987-05-22 | 1990-02-27 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-COA reductase inhibitors |
US5091378A (en) * | 1987-05-22 | 1992-02-25 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method |
US5185328A (en) * | 1987-08-20 | 1993-02-09 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
DE3739882A1 (de) * | 1987-11-25 | 1989-06-08 | Bayer Ag | Substituierte hydroxylamine |
US4868185A (en) * | 1987-12-10 | 1989-09-19 | Warner-Lambert Company | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
EP0326386A3 (en) * | 1988-01-27 | 1990-04-25 | May & Baker Limited | Isoquinolinones |
US4822799A (en) * | 1988-01-27 | 1989-04-18 | Sandoz Pharm. Corp. | Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals |
NO890522L (no) * | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte imidazolinoner og imidazolinthioner. |
US5024999A (en) * | 1988-04-26 | 1991-06-18 | Nissan Chemical Industries Ltd. | Pyrazolopyridine type mevalonolactones useful as pharmaeuticals |
JP2890448B2 (ja) * | 1988-04-26 | 1999-05-17 | 日産化学工業株式会社 | ピラゾロピリジン系メバロノラクトン類 |
US4870187A (en) * | 1988-08-23 | 1989-09-26 | Bristol-Myers Company | Antihypercholesterolemic tetrazol-1-yl compounds |
US5010205A (en) * | 1988-08-23 | 1991-04-23 | Bristol-Myers Company | Antihypercholesterolemic tetrazol-1-yl intermediates |
NZ230121A (en) * | 1988-08-29 | 1993-08-26 | Squibb & Sons Inc | Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels |
US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
KR0162656B1 (ko) * | 1988-10-13 | 1999-01-15 | 로쓰 비엠, 하우스 한스-루돌프 | 7-치환된-헵트-6-엔산 및 -헵탄산과 그의 유도체 및 그의 중간체의 제조방법 |
JPH04270285A (ja) * | 1988-11-14 | 1992-09-25 | Nissan Chem Ind Ltd | ピラゾロピリミジン系メバロノラクトン類 |
DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
GB8919091D0 (en) * | 1989-08-22 | 1989-10-04 | Fujisawa Pharmaceutical Co | Pyrroloquinoline compounds |
IT1237792B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
DE4243279A1 (de) * | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
JP2736599B2 (ja) * | 1993-07-23 | 1998-04-02 | 株式会社キッツ | ボールバルブのシート構造 |
US6425881B1 (en) | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
ES2194202T3 (es) * | 1996-06-24 | 2003-11-16 | Novartis Ag | Compuestos polimorfos. |
EP0988289A2 (en) | 1997-06-05 | 2000-03-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds, their production and use |
AU767154B2 (en) | 1998-11-20 | 2003-10-30 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
EP1284964A1 (en) | 2000-05-26 | 2003-02-26 | Ciba SC Holding AG | Process for the preparation of indole derivatives and intermediates of the process |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
CN1509180A (zh) | 2001-04-18 | 2004-06-30 | ԭ���ø� | 用脂肪族聚胺治疗综合症x的方法 |
AU2002333271B2 (en) * | 2001-08-03 | 2007-08-09 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of fluvastatin sodium |
US6696473B2 (en) | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
EP1496897A4 (en) | 2002-04-12 | 2006-05-10 | Merck & Co Inc | INHIBITORS OF TYROSINE KINASES |
CA2535359A1 (en) | 2003-08-21 | 2005-03-03 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
CN100404479C (zh) * | 2003-08-27 | 2008-07-23 | 住友化学株式会社 | 芳族不饱和化合物的制备方法 |
US8227434B1 (en) | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
US7709508B2 (en) | 2004-12-09 | 2010-05-04 | Merck Sharp & Dohme | Estrogen receptor modulators |
CA2590860C (en) | 2004-12-09 | 2011-05-03 | Merck & Co., Inc. | Estrogen receptor modulators |
PL1855674T3 (pl) | 2005-03-02 | 2015-01-30 | Merck Sharp & Dohme | Kompozycja do hamowania katepsyny K |
KR101363278B1 (ko) | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 lxr 변조제 |
WO2007017117A1 (en) * | 2005-07-28 | 2007-02-15 | Lek Pharmaceuticals D.D. | Process for the synthesis of rosuvastatin calcium |
US8440695B2 (en) | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
ATE431818T1 (de) | 2006-04-20 | 2009-06-15 | Italiana Sint Spa | Verfahren zur herstellung von fluvastatin-natrium |
RS53461B (en) | 2006-07-05 | 2014-12-31 | Takeda Gmbh | COMBINATION OF HMG-COA REDUCTASE INHIBITOR OR SIMVASTATIN WITH PHOSPHODIESTERASE 4 INHIBITOR AS A ROFLUMILAST FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
KR20100017866A (ko) | 2007-05-21 | 2010-02-16 | 노파르티스 아게 | Csf-1r 억제제, 조성물 및 사용 방법 |
ES2330184B1 (es) | 2008-06-03 | 2010-07-05 | Neuron Biopharma, S.A. | Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores. |
SI2373609T1 (sl) | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
CA2761934C (en) | 2009-05-28 | 2018-01-09 | Exelixis Patent Company Llc | Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators |
WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EA201290919A1 (ru) | 2010-03-16 | 2013-03-29 | Дана-Фарбер Кэнсер Инститьют, Инк. | Индазольные соединения и их применение |
US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
JPWO2012046772A1 (ja) | 2010-10-06 | 2014-02-24 | 国立大学法人 東京大学 | リンパ浮腫予防治療剤 |
WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | C−jun−n−末端キナーゼ(jnk)の阻害剤 |
KR20140108705A (ko) | 2011-12-29 | 2014-09-12 | 트러스티즈 오브 터프츠 칼리지 | 재생 및 염증 반응을 제어하기 위한 생체물질의 기능화 |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
JP6442475B2 (ja) | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lxr調節因子 |
EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
AU2014332250B2 (en) | 2013-10-08 | 2018-07-19 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2015051479A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
WO2015120580A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
-
1983
- 1983-11-18 HU HU84284A patent/HU204253B/hu unknown
- 1983-11-18 WO PCT/EP1983/000308 patent/WO1984002131A1/de active IP Right Grant
- 1983-11-18 AU AU22612/83A patent/AU570021B2/en not_active Expired
- 1983-11-21 NZ NZ206338A patent/NZ206338A/en unknown
- 1983-11-21 IL IL70286A patent/IL70286A/xx not_active IP Right Cessation
- 1983-11-21 IE IE2713/83A patent/IE56262B1/en not_active IP Right Cessation
- 1983-11-21 GR GR73028A patent/GR79042B/el unknown
- 1983-11-22 LU LU88670C patent/LU88670I2/fr unknown
- 1983-11-22 AT AT83810548T patent/ATE31718T1/de active
- 1983-11-22 CA CA000441684A patent/CA1210405A/en not_active Expired
- 1983-11-22 DE DE8383810548T patent/DE3375137D1/de not_active Expired
- 1983-11-22 DE DE1994175017 patent/DE19475017I2/de active Active
- 1983-11-22 EP EP83810548A patent/EP0114027B1/en not_active Expired
-
1984
- 1984-06-28 FI FI842615A patent/FI77228C/fi not_active IP Right Cessation
- 1984-07-20 DK DK359284A patent/DK359284A/da not_active Application Discontinuation
-
1990
- 1990-04-19 DK DK097890A patent/DK165244C/da not_active IP Right Cessation
- 1990-05-11 JP JP2120164A patent/JPH0347167A/ja active Granted
-
1991
- 1991-02-06 HK HK111/91A patent/HK11191A/xx not_active IP Right Cessation
- 1991-12-20 CY CY1579A patent/CY1579A/xx unknown
-
1995
- 1995-09-28 NL NL950022C patent/NL950022I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
NL950022I2 (nl) | 1996-12-02 |
EP0114027A1 (en) | 1984-07-25 |
DE19475017I2 (de) | 2003-02-20 |
AU2261283A (en) | 1984-06-18 |
FI77228C (fi) | 1989-02-10 |
DK359284D0 (da) | 1984-07-20 |
FI77228B (fi) | 1988-10-31 |
IE832713L (en) | 1984-05-22 |
GR79042B (da) | 1984-10-02 |
WO1984002131A1 (en) | 1984-06-07 |
DK165244B (da) | 1992-10-26 |
FI842615A0 (fi) | 1984-06-28 |
DK165244C (da) | 1993-03-22 |
CA1210405A (en) | 1986-08-26 |
DK359284A (da) | 1984-07-20 |
ATE31718T1 (de) | 1988-01-15 |
IE56262B1 (en) | 1991-06-05 |
DE3375137D1 (en) | 1988-02-11 |
FI842615A (fi) | 1984-06-28 |
DK97890A (da) | 1990-04-19 |
EP0114027B1 (en) | 1988-01-07 |
JPH0347167A (ja) | 1991-02-28 |
CY1579A (en) | 1991-12-20 |
LU88670I2 (fr) | 1996-04-29 |
HU204253B (en) | 1991-12-30 |
AU570021B2 (en) | 1988-03-03 |
IL70286A (en) | 1987-08-31 |
HK11191A (en) | 1991-02-13 |
IL70286A0 (en) | 1984-02-29 |
HUT35642A (en) | 1985-07-29 |
JPH0440343B2 (da) | 1992-07-02 |
NZ206338A (en) | 1987-08-31 |
NL950022I1 (da) | 1996-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK97890D0 (da) | Fremgangsmaade til fremstilling af mevalolactonanaloge | |
NZ214402A (en) | Indene derivatives and pharmaceutical compositions | |
ATE181482T1 (de) | Herbizide zusammensetzungen in form einer diphenylether- und stickstofflösung und verfahren | |
PT80674A (en) | Process for the preparation of pyrazole analogues of mevalonolactone and derivatives thereof | |
ES529090A0 (es) | Procedimiento para preparar analogos de mevalonolactona y derivados de los mismos | |
EP0086756A3 (en) | Dermatological compositions based on mercaptopropionylamidoacetic thiol esters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CTFF | Application for supplementary protection certificate (spc) filed |
Free format text: CA 1996 00001, 960118 |
|
CTFG | Supplementary protection certificate (spc) issued |
Free format text: CA 1996 00001, 960118, EXPIRES: 20080823 |
|
PUP | Patent expired |